ABSOLUTE Randomized Comparison between
Sirolimus (Cypher)/Sirolimus-analogous (Xience; Promus) vs. Paclitaxel
(Taxus vs.Costar) Eluting Stents in Coronary Lesions: a Single Center
Experience
ABSOLUTE Trial
Randomized Comparison between Sirolimus (Cypher)/Sirolimus-analogous
(Xience; Promus) vs. Paclitaxel (Taxus vs.Costar) Eluting Stents in
Coronary Lesions: a Single Center Experience
ABSORB First-ever human
trial of a fully bioabsorbable everolimus-eluting stent. Presented at
ACC 2007 by Dr. Patrick Serruys
ARCHER Stenting of the
internal carotid artery using the Guidant ACCULINK™ Carotid Stent System
with or without the ACCUNET™ Embolic Protection System
Association of DES with Impaired Collateral
Function Meier et al
BASKET Basel Stent
Cost-Effectiveness (BASKET) Trial
Canadian SIRIUS
Canadian study of sirolimus-eluting stents vs uncoated stents
Clopidogrel Use and Long-term Clinical Outcomes after Drug Eluting Stent
Implantation Eisenstein et al.,
CRUSADE Quality Improvement Initiative Impact
of DES on Revascularization Choices in Patients with Acute Coronary
Syndromes and Multivessel Coronary Disease
Delayed-RRISC Trial Long term events in DES: A
specific focus on the treatment of diseased saphenous vein grafts by
Pierfrancesco Agostoni M.D. and Paul Vermeersch M.D.
DELIVER
paclitaxel-coated RX ACHIEVE™
Drug-Eluting Coronary Stent System (CSS) vs. the metallic MULTI-LINK RX
PENTA™ CSS in patients with de novo coronary lesions
DIABETes and Sirolimus Eluting Stent Trial Long term Follow-up
by Manel Sabate, M.D. et al.
DIABETES
Sirolimus-eluting stents vs bare metal stents among diabetic patients
undergoing PCI
DIRECT
direct stenting vs predilatation in patients
receiving sirolimus-eluting stents for treatment of single, de novo
lesions
Drug-Eluting and Bare Metal Stenting for Diabetes Mellitus: Results from
the Mass-DAC Registry by Dr. Laura Mauri
ENDEAVOR 4 A Randomized Comparison of a
Zotarolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients
with Coronary Artery Disease
ENDEAVOR 4 Trial A Randomized Comparison of a
Zotarolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients
with Coronary Artery Disease
Endeavor Pooled Analysis of Early and Late
Safety of a Zotarolimus-Eluting Stent (Safety Results)
EuroSTAR II The European Randomized CoStar
Trial: Cobalt-Chromium Paclitaxel-eluting Stent vs. identical BMS
Evaluation by Optical Coherence Tomography (OCT) of
Neointimal Coverage of Sirolimus-Eluting Stent Three Months
After Implantation
Evaluation by Optical Coherence Tomography (OCT) of
Neointimal Coverage of Sirolimus-Eluting Stent Three Months
After Implantation Masamichi
Takano, MD. et al
FAILS
Incidence and management of
restenosis after treatment of unprotected left main disease
with drug-eluting stents: 70 restenotic cases from a cohort
of 718 patients - Failure in Left Main Study by Dr. Giuseppe
Biondi-Zoccai
ISAR-TEST 3 Rapamycin-Eluting
Stents With Different Polymer Coating to Reduce Restenosis
LONG DES II Sirolimus-Eluting
Stent Versus Paclitaxel-Eluting Stent in the Treatment of
Long Native Coronary Lesions
Long Term Clinical Outcomes Following Drug-Eluting and Bare
Metal Stenting in Massachusetts
NORDIC Bifurcation Trial Presented
at TCT 2006
PACCOCATH ISR 1 and 2 A
Prospective, Randomized Trial of a Paclitaxel-Eluting
Balloon in In-Stent Restenosis (2-Year Results)
PACCOCATH ISR Treatment of
In-Stent Restenosis by Paclitaxel Coated PTCA Balloons. AHA
2006
PASSION Taxus vs Bare Metal stent
in STEMI
PROGRESS 1 First in man
bioabsorbable stent
PROGRESS-AMS Clinical performance
and angiographic results of coronary stenting with
Absorbable Metal Stents
Rapamycin- vs Paclitaxel-Eluting Stents
RAVEL
Long-term (1 term) Sirolimus
releasing stents (Cypher) vs standard uncoated stents in
patients undergoing PCI
REALITY
Sirolimus-eluting stents (Cypher) vs
paclitaxel-eluting stents (Taxus) among patients with de
novo coronary lesions
SCAAR Drug Eluting Stents Vs. Bare
Metal Stents in Sweden
SCANDSTENT Cypher stenting in
complex disease
SESAMI Sirolimus Stent vs Bare
Stent in Acute Myocardial Infarction Trial
SESAMI Trial Randomized Trial of
Sirolimus Stent Vs Bare Metal Stent in Acute Myocardial
Infarction
SESAMI Trial
Randomized Trial of Sirolimus Stent Vs
Bare Metal Stent in Acute Myocardial Infarction by Mauricio
Menichelli, MD, et al.
Sidebranch Stenting Trial
SIRIUS Economic Results
Cost-effectiveness of sirolimus-eluting stents for treatment
of complex coronary stenoses
SIRIUS Efficacy of
sirolimus-eluting coated stent in native coronary lesions
*Results presented at EURO PCR 2002
SIRIUS Efficacy of sirolimus-eluting coated stent in native
coronary lesions *Results presented at TCT 2002
SIRTAX Randomized, single center trial
of Cypher vs Taxus, no industry support
SPIRIT III A Prospective, Randomized Trial Comparing an
Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with
Coronary Artery Disease 1-Year Follow-Up and Subgroup Analysis
SPIRIT III Clinical,
Angiographic, and IVUS Results from the Pivotal U.S. Randomized SPIRIT
III Trial of the XIENCE V Everolimus-eluting Coronary Stent System
Stent Fractures by Dr. Jeffrey Popma
STRATEGY Sirolimus Eluting Stents Vs. Bare Metal Stents
Implantation Assisted by Systematic GP IIb/IIIa Infusion in Patients
with MI
TAXUS 2 and 4 Two Year Results
TAXUS 2 Moderate release paclitaxel-eluting stent vs bare
stent in de novo lesions *Presented at TCT 2002
TAXUS 2 Slow release paclitaxel-eluting stent vs bare stent
in de novo lesions *Presented at TCT 2002
Taxus ATLAS
Evaluation of TAXUS Liberté vs. TAXUS Express Trial
TAXUS
ATLAS SMALL VESSEL and LONG LESION: First Report of
Nine-Month Clinical and Angiographic Results
TAXUS
ATLAS WORKHORSE and DIRECT STENT First Report of Nine and
Twelve Month Clinical and Angiographic Results
TAXUS
ATLAS: SMALL VESSEL and LONG LESION First Report of
Nine-Month Clinical and Angiographic Results
TAXUS IV 2 Year follow up data
TAXUS IV
Slow-rate release polymer-based paclitaxel-eluting stent compared with
bare stent in patients with single de novo coronary lesions
TAXUS V
Efficacy of the slow-rate release polymer-based paclitaxel-eluting stent
compared with bare stent in patients with single complex coronary
lesions
TAXUS V
ISR Trial of Taxus stent vs brachytherapy for in stent
Taxus:
Myonecrosis and Sidebranch patency by Dr. Jeffrey J. Popma
restenosis
TYPHOON
Cypher vs Bare metal stent in STEMI
ZoMaxx
Stent
